Xeris Biopharma Holdings Stock Price, News & Analysis

Xeris Biopharma (Nasdaq: XERS) has strengthened its intellectual property portfolio with a new U.S. patent for Recorlev® (levoketoconazole), now listed in the FDA's Orange Book. The patent (No. 12,377,096) covers therapeutic uses that minimize drug-drug interactions between levoketoconazole and MATE1 substrates, extending protection until March 2040.

Recorlev, approved by the FDA in December 2021 for treating endogenous Cushing's syndrome in adult patients where surgery isn't an option, now holds four Orange Book-listed patents. The drug represents a significant advancement for patients with this rare endocrine disease, with Xeris continuing to invest in education, patient support, and market access initiatives.

Xeris Biopharma (Nasdaq: XERS) reported exceptional Q2 2025 financial results, with total revenue surging 49% year-over-year to $71.5 million. The company's flagship product Recorlev® led growth with a 136% YoY increase to $31.4 million, driven by a 122% rise in patient numbers. Gvoke® revenue grew 17% to $23.5 million, while Keveyis® declined 13% to $11.5 million.

The company significantly improved its bottom line, reducing net loss by 87% to $1.9 million ($0.01 per share) and achieving positive Adjusted EBITDA of $12.5 million. Based on strong performance, Xeris raised its full-year 2025 revenue guidance to $280-290 million from $260-275 million previously. The company also outlined ambitious long-term targets, including $750 million in total revenue by 2030 and nearly $1 billion in Recorlev net revenue by 2035.

Xeris Biopharma (Nasdaq: XERS), a growing biopharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial and operational results. A replay will be available until August 21, 2025 through various dial-in numbers. Investors can access the webcast through the company's investor relations website.

Xeris Biopharma (XERS) hosted its first Analyst and Investor Day, unveiling ambitious growth plans and financial projections. The company reaffirmed its 2025 revenue guidance of $260-275 million while maintaining positive adjusted EBITDA. Looking ahead, Xeris projects total revenue of approximately $750 million by 2030, driven by its product portfolio growth. By 2035, the company expects Recorlev to generate annual net revenue of $1 billion, while its innovative hypothyroidism treatment XP-8121 is projected to achieve peak revenue of $1-3 billion. CEO John Shannon highlighted the company's successful track record in developing and commercializing products for unmet medical needs, with Recorlev's revenue acceleration marking a significant growth inflection point. The company emphasized its financial strength and ability to self-fund future growth through rapid revenue expansion and disciplined capital management.

Xeris Biopharma Holdings (XERS) will host its first hybrid analyst and investor day on June 3, 2025, at 10:00 a.m. EST in New York City. The event will feature presentations from key opinion leaders including Dr. Antonio C. Bianco, Dr. Francesco S. Celi, and Dr. Eliza B. Geer, alongside company management.

The presentations will focus on market dynamics, unmet medical needs, and outlook for Recorlev® and XP-8121, their Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism treatment. The event will include a live Q&A session, with virtual participants able to submit questions. A replay will be available for those unable to attend live.

Xeris Biopharma (XERS) reported strong Q1 2025 financial results with total revenue increasing 48% YoY to $60.1 million. The company's flagship product Recorlev saw exceptional growth with revenue up 141% YoY to $25.5 million, driven by a 124% increase in patient numbers. Gvoke revenue grew 26% to $20.8 million, while Keveyis revenue declined 13% to $11.4 million. The company tightened its full-year 2025 revenue guidance to $260-275 million from the previous $255-275 million range. Net loss for Q1 was $9.2 million ($0.06 per share), with Adjusted EBITDA positive at $4.4 million, an $8.4 million improvement YoY. The company will host an Analyst & Investor Day on June 3rd, 2025, in New York City.

Xeris Biopharma (Nasdaq: XERS), a growth-oriented biopharmaceutical company, has scheduled the release of its first quarter 2025 financial results for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss their financial and operational performance.

Interested participants can pre-register for the call through the provided link. A replay of the conference call will be available until May 22, 2025, through various international dial-in numbers. Additionally, stakeholders can access the webcast through the company's investor relations page.

Xeris Biopharma Holdings (Nasdaq: XERS) announced changes to its Board of Directors. Ricki Fairley has resigned effective immediately, while John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the board size to eight members.

The company has appointed James Brady as a new director to fill the immediate vacancy. Brady brings over thirty years of experience from AstraZeneca, where he held various leadership positions, most recently serving as Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. He currently serves on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA).

Xeris Biopharma Holdings (Nasdaq: XERS) has received FDA approval for its supplemental new drug application (sNDA) of Gvoke VialDx™, the first concentrated, ready-to-dilute liquid glucagon for use as a diagnostic aid during radiologic examinations in adult patients.

The company has partnered with American Regent for commercialization in the U.S., with Xeris handling product supply while American Regent manages commercialization efforts. The product will be available in 1-count or 10-count packages of 1 mg per 0.2 mL single-dose vials, with market availability expected in Q3 2025.

This development targets the growing procedural gastroenterology market, with an estimated 20 million gastrointestinal endoscopic procedures performed annually. The product is designed to temporarily inhibit movement of the gastrointestinal tract in adult patients during radiologic examinations.